Regeneron Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Regeneron Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: New York
Headquarters city: Tarrytown
Headquarters state / province: New York
Headquarters country: United States
Fiscal year end: December
Ticker symbol: REGN
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000872589
EIN: 13-3444607
Wikidata ID: Q7308054

Board of directors

Follow this board

Arthur F. Ryan · Director
Since 2023
Bonnie L. Bassler · Director
Since 2023
Christine A. Poon · Director
Since 2023
Craig B. Thompson · Director
Since 2023
David P. Schenkein · Director
Since 2023
George L. Sing · Director
Since 2023
George Yancopoulos · Director · Bd. Co-Chair, President & CSO
Since 2023
Huda Y. Zoghbi · Director
Since 2023
Joseph L. Goldstein · Director
Since 2023
Kathryn Guarini · Director
Since 2023
Leonard S. Schleifer · Director · Bd. Co-Chair, President & CEO
Since 2023
Marc Tessier-Lavigne · Director
Since 2023
Michael S. Brown · Director
Since 2023
N. Anthony Coles · Director
Since 2023
P. Roy Vagelos · Director
Since 2023

Chief executives

Leonard S. Schleifer · President & CEO

Dates unknown

Director election results

Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

5 of this board's directors also sit on 8 other boards. 6 are in the same sector.

Shared director Other board Same sector

Denali Therapeutics Inc. Same sector
via David P. Schenkein and Marc Tessier-Lavigne
Agios Pharmaceuticals Inc. Same sector
via David P. Schenkein
Charles River Laboratories International Inc. Same sector
via Craig B. Thompson
Neurocrine Biosciences Inc. Same sector
via Christine A. Poon
Prime Medicine Inc. Same sector
via David P. Schenkein
Prudential Financial Inc.
via Christine A. Poon
Royalty Pharma plc Same sector
via Bonnie L. Bassler
The Sherwin-Williams Company
via Christine A. Poon

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $54,726,721; 107 sales by 10 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Option exercise	+1,500	$726.53	$1,089,795
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Option exercise	+1,478	$644.54	$952,630
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Option exercise	+905	$492.00	$445,260
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−439	$939.57	$412,471
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−575	$940.46	$540,765
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−982	$941.58	$924,632
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−1,215	$942.31	$1,144,907
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−529	$943.53	$499,127
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−108	$944.22	$101,976
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−35	$945.61	$33,096
Nov 4, 2026	Pitofsky Jason Officer (SVP Controller)	Open-market sale	−179	$950.76	$170,186
Nov 3, 2026	MURPHY ANDREW J Officer (Co-Chief Scientific Officer)	Gift	−1,054	—	—
Nov 3, 2026	Huda Y. Zoghbi Director	Option exercise	+7,439	$380.95	$2,833,887
Nov 3, 2026	Huda Y. Zoghbi Director	Open-market sale	−6,939	$970.42	$6,733,744
Nov 3, 2026	Huda Y. Zoghbi Director	Open-market sale	−500	$971.06	$485,530

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Regeneron Pharmaceuticals Inc.

Who is the CEO of Regeneron Pharmaceuticals Inc.?

Leonard S. Schleifer is Regeneron Pharmaceuticals Inc.'s President & CEO.

How many directors are on Regeneron Pharmaceuticals Inc.'s board?

Regeneron Pharmaceuticals Inc.'s board has 15 directors: Arthur F. Ryan, Bonnie L. Bassler, Christine A. Poon, Craig B. Thompson, David P. Schenkein, George L. Sing, George Yancopoulos, Huda Y. Zoghbi, Joseph L. Goldstein, Kathryn Guarini and 5 others.

Are Regeneron Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Regeneron Pharmaceuticals Inc. insiders made no open-market purchases and sold $54.7 million of shares in 107 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Regeneron Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="regeneron-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.